Sugi Predict

Sugi Predict / Targets / BBC3

BBC3

Bcl-2-binding component 3, isoforms 1/2 (JFY- · Q9BXH1 · BBC3 on Sugi Atlas →

2,173 patent compounds predicted against BBC3, 2,090 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Abt 737 Abt 737 (SCHEMBL158942) 1.00 1/20
Abt 737 Abt 737 (SCHEMBL170470) 1.00 1/20
Abt 737 Abt 737 (SCHEMBL1541072) 1.00 1/20
SCHEMBL1540670 SCHEMBL1540670 0.93 1/20
SCHEMBL1540214 SCHEMBL1540214 0.92 1/20
SCHEMBL1540387 SCHEMBL1540387 0.92 1/20
SCHEMBL1540510 SCHEMBL1540510 0.92 1/20
SCHEMBL1540736 SCHEMBL1540736 0.92 1/20
SCHEMBL680873 SCHEMBL680873 0.91 1/20
SCHEMBL1540180 SCHEMBL1540180 0.90 1/20
SCHEMBL1540466 SCHEMBL1540466 0.90 1/20
SCHEMBL1540142 SCHEMBL1540142 0.90 1/20
SCHEMBL1540348 SCHEMBL1540348 0.89 1/20
SCHEMBL1540686 SCHEMBL1540686 0.89 1/20
SCHEMBL1540047 SCHEMBL1540047 0.89 1/20
SCHEMBL1540376 SCHEMBL1540376 0.89 1/20
SCHEMBL1540469 SCHEMBL1540469 0.89 1/20
SCHEMBL1540067 SCHEMBL1540067 0.89 1/20
SCHEMBL1540020 SCHEMBL1540020 0.88 1/20
SCHEMBL1541099 SCHEMBL1541099 0.88 1/20

Clinical trials — most relevant to BBC3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) PHASE3RECRUITING
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML PHASE2ACTIVE_NOT_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission PHASE2ACTIVE_NOT_RECRUITING
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer PHASE2COMPLETED
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma PHASE1/PHASE2WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML PHASE1RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Circulating Markers for Ischemic Heart Disease nanRECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Smoking Influence on Apoptosis in Periodontitis nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BBC3 binder may also engage these)

ProteinNameSimilarity
Q99ML1 — 1.000 Q99ML1 →
Q80ZG6 — 0.999 Q80ZG6 →
F8WCM5 — 0.980 F8WCM5 →
Q9BQY9 — 0.979 Q9BQY9 →
Q92837 — 0.979 Q92837 →
Q8N4B5 — 0.977 Q8N4B5 →
Q95K74 — 0.976 Q95K74 →
Q8IYJ0 — 0.976 Q8IYJ0 →
Q6ZUT6 — 0.976 Q6ZUT6 →
Q86SH2 — 0.976 Q86SH2 →
P57055 — 0.976 P57055 →
A6NN90 — 0.975 A6NN90 →
Q5SV97 — 0.975 Q5SV97 →
Q8N944 — 0.975 Q8N944 →
Q6P1B3 — 0.975 Q6P1B3 →
Q6ZMY3 — 0.975 Q6ZMY3 →
A6NNL0 — 0.974 A6NNL0 →
Q7TN08 — 0.974 Q7TN08 →
Q8NAV2 — 0.974 Q8NAV2 →
Q2TAM9 — 0.973 Q2TAM9 →
Q3UM83 — 0.973 Q3UM83 →
Q9BUA3 — 0.973 Q9BUA3 →
Q6NZ36 — 0.973 Q6NZ36 →
Q6UXU0 — 0.973 Q6UXU0 →
Q2M3G4 — 0.972 Q2M3G4 →
Q5VTJ3 — 0.972 Q5VTJ3 →
Q9GMA3 — 0.972 Q9GMA3 →
Q8TAB5 — 0.972 Q8TAB5 →
I3L1E1 — 0.972 I3L1E1 →
H3BQW9 — 0.971 H3BQW9 →